Libtayo® (cemiplimab) in Non-small cell lung cancer
by Dr. C.H. Weaver M.D. 2/2021
About Libtayo (cemiplimab-rwlc)
Libtayo is a fully human monoclonal antibody precision medicine know as a “checkpoint inhibitor”. Libtayo targets the immune checkpoint receptor PD-1 on T-cells. By binding to PD-1, Libtayo block cancer cells from using the PD-1 pathway to suppress T-cell activation.
In a phase III clinical trial called EMPOWER-Lung 1 Libtayo was compared to platinum-doublet chemotherapy in patients with squamous or non-squamous advanced NSCLC that tested positive for PD-L1 in ≥50% of tumor cells, but not for ALK, EGFR or ROS1. The PD-1 inhibitor Libtayo® (cemiplimab) when compared to platinum-doublet chemotherapy in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with ≥50% PD-L1 expression in tumor cells extends overall survival and reduces the risk of death by 43% among those with confirmed PD-L1 expression of 50% or higher.
Libtayo is no yet FDA approved in the United States but undergoing review. When approved it will represent the 5th PD-1 checkpoint inhibitor approved for the treatment of NSCLC.